Drug Name: Retigabine
Company: GlaxoSmithKline, GSK
Drug Type: Small Molecule
Conditions: ALS, Epilepsy
Mechanism Type: Neuronal hyperexcitability
Mechanism: Retigabine is a Kv7 potassium channel activator that may reduce neuronal hyperexcitability by helping neurons return to the resting state upon firing.
U.S. Status for ALS: Phase II

[1] Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Wainger, BJ et al., Cell Rep. 2014 Apr 10;7(1):1-11.

Last updated March 21st, 2017

Share this: